Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 7285639
Antibody to telomerase reverse transcriptase
granted -
US 7285527
Tumor radiosensitization using gene therapy
granted -
US 7285534
Corticotropin-releasing hormone analogs and their uses
granted -
US 7285542
Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
granted -
US 7285415
Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
granted -
US 7282563
Opioid receptors and methods of use
granted -
US 7282482
NGF for the prevention of demyelination in the nervous system
granted -
US 7279322
Electrospraying apparatus and method for coating particles
granted -
US 7279306
Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
granted -
US 7279466
Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof
granted -
US 7276348
Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
granted -
US 7276643
Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
granted -
US 7276352
Induction of Ξ² cell differentiation in human cells by stimulation of the GLP-1 receptor
granted -
US 7273713
Methods of modulating mitochondrial NAD-dependent deacetylase
granted -
US 7273613
Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders
granted -
US 7271148
Inhibition of cellular proteases
granted -
US 7271161
Platinum complexes as antitumor agents in combination with biochemical modulation
granted -
US 7268148
Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
granted -
US 7267978
Chimeric transcriptional regulatory element compositions and methods for increasing prostate-targeted gene expression
granted -
US 7265083
Treatment of idiopathic pulmonary fibrosis using IP-10
granted -
US 7264816
Virulent systemic feline calicivirus
granted -
US 7264804
Kits for detecting anti-SIRS antibodies
granted -
US 7265091
Methods and compositions for treating male erectile dysfunction
granted -
US 7264820
Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline
granted -
US 7265208
Fusion molecules and treatment of IgE-mediated allergic diseases
granted -
US 7261882
Methods for treating neuropathic pain by administering IL-10 polypeptides
granted -
US 7261875
Dendritic poly (amino acid) carriers and methods of use
granted -
US 7262288
Nucleic acids encoding human telomerase reverse transcriptase and related homologs
granted -
US 7259236
RBP1L1, a novel retinoblastoma binding protein-related gene encoding an antigenic epitope and methods of using thereof
granted -
US 7256171
Use of core 2 G1cNAc transferase inhibitors in treating inflammation
granted -
US 7256277
Nucleotide and protein sequence of mammastatin and methods of use
granted -
US 7256047
Measurement of gluconeogenesis and intermediary metabolism using stable isotopes
granted -
US 7256265
Streptococcal C5a peptidase vaccine
granted -
US 7255850
Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis
granted -
US 7253185
Amino ceramide-like compounds and therapeutic methods of use
granted -
US 7252819
Methods and compositions for correction of cardiac conduction disturbances
granted -
US 7252989
Adenovirus supervector system
granted -
US 7253275
Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
granted -
US 7250400
Peptides and derivatives thereof showing cell attachment, spreading and detachment activity
granted -
US 7247303
Selected antibody CDRs for binding to aminophospholipids
granted -
US 7247316
Compositions and methods for treating lymphoma
granted -
US 7247708
Modified vitamin K-dependent polypeptides
granted -
US 7244435
DNA vaccine expressing HA1 of equine-2 influenza virus
granted -
US 7244423
Methods for therapy of neurodegenerative disease of the brain
granted -
US 7244450
Compositions and methods for treating lymphoma
granted -
US 7244617
Diminishing viral gene expression by promoter replacement
granted -
US 7244760
Methods for preparation and use of psorospermin analogs
granted -
US 7244557
Method of screening modulators of Nod1 signaling
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory